세계의 안과용 의약품 시장 규모, 점유율, 동향 분석 : 약물 종류별, 질환별, 투여 방법별, 투여 경로별, 제품 종류별, 의약품 종류별, 지역별, 부문별 예측(2025-2030년)

Ophthalmic Drugs Market Size, Share & Trends Analysis Report By Drug Class (Steroidal drugs, Anti-VEGF Agents), By Disease, By Dosage Form, By Route of Administration, By Product Type, By Drug Type, By Region, And Segment Forecasts, 2025 - 2030

US $ 5,950 ￦ 8,302,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 9,698,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,488,000

Printable PDF & Excel (Enterprise License)

보고서 구매 기업 및 그 자회사, 관계사가 사용할 수 있는 라이선스이며, PDF 및 엑셀 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능합니다.

한글목차

안과용 의약품 시장 성장과 동향:

Grand View Research, Inc.의 최신 보고서에 따르면, 세계 안과용 의약품 시장 규모는 2030년까지 620억 8,000만 달러에 달할 것으로 예상되며, 2025년부터 2030년까지 8.5%의 CAGR로 성장할 것으로 예상됩니다.

안과 질환에 대한 인식이 높아지고 안과용 의약품에 대한 수요가 급증하는 것이 시장 성장을 촉진하는 요인입니다. 또한, 노화성 황반변성, 백내장, 안구건조증, 당뇨망막병증, 녹내장 등 안과 질환의 유병률 증가는 안과용 의약품의 수요를 증가시킬 것으로 예상됩니다.

BrightFocus Foundation에 따르면, 2021년에는 300만 명 이상의 미국인이 녹내장을 앓고 있는 것으로 추정되며, 그 중 270만 명 이상이 가장 흔한 유형의 녹내장, 즉 개방각 녹내장을 앓고 있는 것으로 추정됩니다. 또한, 미국에서는 330만 명이 실명이나 약시의 영향을 받고 있습니다. 녹내장 및 실명의 주요 위험인자로는 고령, 가족력, 얇은 각막, 높은 안압 등을 들 수 있습니다. 따라서 안과용 의약품에 대한 폭넓은 인구 기반이 형성되어 있어 유리한 성장이 확실시되고 있습니다.

또한, 안과 치료 및 약물전달 기업들은 신약 개발 기술 발전을 위한 연구 개발을 촉진하기 위해 자금 지원을 받고 있으며, 이는 시장 성장을 촉진할 가능성이 높습니다. 예를 들어, 2020년 6월 Re-Vana Therapeutics는 Qubis, ExSight Ventures, LLC, Clarendon Fund Managers, Visionary Ventures, Techstart Ventures LLP 등으로부터 시리즈 A로 325만 달러의 투자를 유치했습니다. 이번 투자 유치로 리바나 테라퓨틱스의 EyeLief와 OcuLief의 생분해성 기술 개발이 가속화되어 저분자 및 생물학적 제제 전달에 사용될 수 있을 것으로 기대됩니다.

Safe Eyes America에 따르면 안과 질환의 가장 흔한 위험 요인은 고령, 가족력, 당뇨병, 고혈압 등이며, 노인 인구의 증가가 안과용 의약품 시장 성장의 주요 촉진요인으로 작용하고 있습니다. 예를 들어, America's HEALTH RANKINGS senior report 2021에 따르면 미국에는 65세 이상 성인이 5,400만 명 이상 거주하고 있으며, 이 인구는 전체 인구의 16.5%를 차지하는 것으로 추정됩니다. 황반변성 조사에 따르면 AMD는 60세 이상 미국인의 실명 원인 1위로 나타났습니다.

안과용 제품에 대한 지속적인 약사 승인은 시장 성장을 뒷받침하고 있는 것으로 보입니다. 예를 들어, 산텐제약은 2022년 6월 안구건조증 치료제 '디쿠아스 LX 점안액'의 일본 내 제조판매 승인을 획득했다고 발표했습니다. 이 점안액은 투여 횟수를 줄여 환자의 순응도를 높인 개량형 제제입니다.

안과용 의약품 시장 : 분석 개요

• 항 VEGF 약물 부문은 수요 증가와 적은 부작용으로 인해 2024년 가장 큰 점유율을 차지했습니다.
• 망막 질환은 노화성 황반변성 및 당뇨망막병증의 유병률 증가로 인해 2024년 가장 큰 시장 점유율을 차지했습니다.
• 국소 투여 경로는 표적 부위에 약물을 전달할 수 있는 장점과 사용 편의성 등의 요인으로 인해 2024년 시장을 독점했습니다.
• 점안제에 대한 수요 증가, 환자들의 높은 순응도, OTC 제품의 접근성 등으로 인해 2024년에는 점안제 부문이 가장 큰 점유율을 차지했습니다.
• 아시아태평양은 의료 인프라의 발전, 안과 제품에 대한 수요 증가, 환자 수 증가로 인해 예측 기간 동안 가장 빠른 성장세를 보일 것으로 예상됩니다.

목차

제1장 분석 방법 및 범위

제2장 주요 요약

제3장 안과용 의약품 시장 : 변수, 동향, 범위

• 시장 연관 전망
  • 상부 시장 전망
  • 관련/부수 시장 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• 안과용 의약품 시장 : 분석 툴
  • 업계 분석 : Porter's Five Forces 분석
  • PESTEL 분석

제4장 안과용 의약품 시장 : 약물 종류별 추정·동향 분석

• 부문 대시보드
• 안과용 의약품 시장 : 약물 종류별 변동 분석
• 안과용 의약품 시장 : 시장 규모 예측과 동향 분석, 약물 종류별(2018-2030년)
• 항알레르기
• 항VEGF제
• 항염증
  • 비스테로이드제
  • 스테로이드
• 녹내장 예방
• 유전자·세포 치료
• 기타

제5장 안과용 의약품 시장 : 질환별 추정·동향 분석

• 부문 대시보드
• 안과용 의약품 시장 : 질환별 변동 분석
• 안과용 의약품 시장 : 시장 규모 예측과 동향 분석, 질환별(2018-2030년)
• 안구건조증
• 알레르기
• 녹내장
• 감염
• 망막 질환
  • 투여 방법별
  • 종류별
• 포도막염
• 기타

제6장 안과용 의약품 시장 : 투여 경로별 추정·동향 분석

• 부문 대시보드
• 안과용 의약품 시장 : 투여 경로별 변동 분석
• 안과용 의약품 시장 : 시장 규모 예측과 동향 분석, 투여 경로별(2018-2030년)
• 국소
• 안구 국소
• 전신

제7장 안과용 의약품 시장 : 투여 방법별 추정·동향 분석

• 부문 대시보드
• 안과용 의약품 시장 : 투여 방법별 변동 분석
• 안과용 의약품 시장 : 시장 규모 예측과 동향 분석, 투여 방법별(2018-2030년)
• 젤
• 안과용 용액·현탁액
• 캡슐·정제
• 안약
• 연고

제8장 안과용 의약품 시장 : 제품 종류별 추정·동향 분석

• 부문 대시보드
• 안과용 의약품 시장 : 제품 종류별 변동 분석
• 안과용 의약품 시장 : 시장 규모 예측과 동향 분석, 제품 종류별(2018-2030년)
• 시판약(OTC)
• 처방약

제9장 안과용 의약품 시장 : 의약품 종류별 추정·동향 분석

• 부문 대시보드
• 안과용 의약품 시장 : 의약품 종류별 변동 분석
• 안과용 의약품 시장 : 시장 규모 예측과 동향 분석, 의약품 종류별(2018-2030년)
• 브랜드 의약품
• 제네릭 의약품

제10장 안과용 의약품 시장 : 지역별 추정·동향 분석

• 시장 점유율 분석 : 지역별(2023년·2030년)
• 시장 대시보드 : 지역별
• 세계 시장 현황 : 지역별
• 시장 규모 예측과 동향 분석(2018-2030년)
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 노르웨이
  • 스웨덴
  • 덴마크
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 호주
  • 한국
  • 태국
• 라틴아메리카
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 남아프리카공화국
  • 사우디아라비아
  • 아랍에미리트
  • 쿠웨이트

제11장 경쟁 구도

• 최근 동향과 영향 분석 : 주요 시장 진출 기업별
• 기업/경쟁 분류
• 벤더 상황
  • 주요 판매대리점 및 채널 파트너 리스트
  • Key customers
  • Key company market share analysis, 2023
  • Alcon
  • Novartis AG
  • Bausch Health Companies, Inc.
  • Merck &Co., Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Coherus BioSciences, Inc.
  • AbbVie, Inc.(Allergan)
  • Pfizer, Inc.
  • Bayer AG
  • Santen Pharmaceutical Co., Ltd.
  • Roche(Genentech, Inc.)
  • Nicox

ksm

영문 목차

영문목차

Ophthalmic Drugs Market Growth & Trends:

The global ophthalmic drugs market size is expected to reach USD 62.08 billion by 2030, garnering a CAGR of 8.5% from 2025 to 2030, according to a new report by Grand View Research, Inc. The rising awareness about ophthalmic disorders and the surge in demand for ophthalmic drugs are the factors propelling the market growth. Moreover, an increase in the prevalence of eye diseases such as age-related macular degeneration, cataract, dry eye, diabetic retinopathy, glaucoma, and others are anticipated to boost the demand for ophthalmic drugs.

According to BrightFocus Foundation in 2021, it is estimated that over 3 million Americans are living with glaucoma, and, among them over 2.7 million patients were affected by the most common type of glaucoma i.e. open-angle glaucoma. Moreover, 3.3 million people are affected by blindness and low vision in the U.S. Some of the major risk factors for glaucoma and blindness are, higher age, family history, thin cornea, and high eye pressure. This creates a wide population base for ophthalmic drugs, thereby, ensuring lucrative growth.

Furthermore, ocular therapeutic and drug delivery companies are receiving funding to expedite R&D for advancements in technologies to develop novel drugs, which is likely to fuel market growth. For instance, in June 2020, Re-Vana Therapeutics received USD 3.25 million in pre-series A funding from Qubis, ExSight Ventures, LLC, Clarendon Fund Managers, Visionary Ventures, and Techstart Ventures LLP. The funding is expected to boost the development of Re-Vana Therapeutics' EyeLief & OcuLief biodegradable technologies that can be used for a small molecule as well as biologics delivery.

Moreover, the rising geriatric population is the key driver for the ophthalmic drugs market growth. According to Safe Eyes America, the most common risk factors for ophthalmic diseases are high age, family history, diabetes, and high blood pressure. For instance, as per AMERICA's HEALTH RANKINGS senior report 2021 it was estimated that more than 54 million adults of age more than 65 live in the U.S., and that population accounted for 16.5% of the total population. According to Macular Degeneration Research AMD is the leading reason for blindness in U.S. people over the age of 60.

Ongoing regulatory approvals for ophthalmic products are likely to support market growth. For instance, in June 2022 Santen Pharmaceutical Co., Ltd announced that it has got marketing and manufacturing approval for the dry eye disease treatment DIQUAS LX ophthalmic solution in Japan. This solution is the improved formulation that has reduced dosing frequency and improved patient compliance.

Ophthalmic Drugs Market Report Highlights:

• Anti-VEGF agents segment held the largest share in 2024 owing to their rising demand and lesser adverse effects
• Retinal disorders held the largest market share in 2024 owing to the rising prevalence of age-related macular degeneration and diabetic retinopathy
• The topical route of administration dominated the market in 2024 owing to factors such as the benefits of the topical route as it delivers the drug to the targeted site and ease of use
• The eye drops segment is expected to hold the largest share in 2024 owing to rising demand for eye drops, high patient compliance, and availability of OTC products
• Asia Pacific is expected to exhibit the fastest growth over the forecast period due to advancements in healthcare infrastructure, increasing demand for eye products, and a large patient pool

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Drug class
  • 1.2.2. Disease
  • 1.2.3. Route of administration
  • 1.2.4. Dosage type
  • 1.2.5. Product type
  • 1.2.6. Drug type
  • 1.2.7. Regional scope
  • 1.2.8. Estimates and forecasts timeline.
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Drug class outlook
  • 2.2.2. Disease outlook
  • 2.2.3. Route of administration outlook
  • 2.2.4. Dosage type outlook
  • 2.2.5. Product type outlook
  • 2.2.6. Drug type outlook
  • 2.2.7. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Ophthalmic Drugs Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook.
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Increasing diseases prevalence
    • 3.2.1.2. String development pipeline
    • 3.2.1.3. Advancements in drug delivery
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Patent expiry of blockbuster drugs
• 3.3. Ophthalmic Drugs Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
  • 3.3.2. PESTEL Analysis

Chapter 4. Ophthalmic Drugs Market: Drug Class Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Ophthalmic Drugs Market: Drug Class Movement Analysis
• 4.3. Ophthalmic Drugs Market Size & Trend Analysis, by Drug Class, 2018 to 2030 (USD Million)
• 4.4. Anti-Allergy
  • 4.4.1. Anti-Allergy market revenue estimates and forecasts, 2018 - 2030 (USD Million)
• 4.5. Anti-VEGF agents
  • 4.5.1. Anti-VEGF agents market revenue estimates and forecasts, 2018 - 2030 (USD Million)
• 4.6. Anti-inflammatory
  • 4.6.1. Anti-inflammatory market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.6.2. Non-steroidal Drugs
    • 4.6.2.1. Non-steroidal Drugs market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.6.3. Steroids
    • 4.6.3.1. Steroids market revenue estimates and forecasts, 2018 - 2030 (USD Million)
• 4.7. Anti-glaucoma
  • 4.7.1. Anti-glaucoma market revenue estimates and forecasts, 2018 - 2030 (USD Million)
• 4.8. Gene & Cell Therapy
  • 4.8.1. Gene & Cell Therapy market revenue estimates and forecasts, 2018 - 2030 (USD Million)
• 4.9. Others
  • 4.9.1. Others market revenue estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 5. Ophthalmic Drugs Market: Disease Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Ophthalmic Drugs Market: Disease Movement Analysis
• 5.3. Ophthalmic Drugs Market Size & Trend Analysis, by Disease, 2018 to 2030 (USD Million)
• 5.4. Dry eye
  • 5.4.1. Dry eye market revenue estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.4.1.1. Gels
      • 5.4.1.1.1. Gels market revenue estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.4.1.2. Eye solutions & suspensions
      • 5.4.1.2.1. Eye solutions & suspensions market revenue estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.4.1.3. Capsules & tablets
      • 5.4.1.3.1. Capsules & tablets market revenue estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.4.1.4. Eye drops
      • 5.4.1.4.1. Eye drops market revenue estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.4.1.5. Ointments
      • 5.4.1.5.1. Ointments market revenue estimates and forecasts, 2018 - 2030 (USD Million)
• 5.5. Allergies
  • 5.5.1. Allergies market revenue estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.5.1.1. Gels
      • 5.5.1.1.1. Gels market revenue estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.5.1.2. Eye solutions & suspensions
      • 5.5.1.2.1. Eye solutions & suspensions market revenue estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.5.1.3. Capsules & tablets
      • 5.5.1.3.1. Capsules & tablets market revenue estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.5.1.4. Eye drops
      • 5.5.1.4.1. Eye drops market revenue estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.5.1.5. Ointments
      • 5.5.1.5.1. Ointments market revenue estimates and forecasts, 2018 - 2030 (USD Million)
• 5.6. Glaucoma
  • 5.6.1. Glaucoma market revenue estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.6.1.1. Gels
      • 5.6.1.1.1. Gels market revenue estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.6.1.2. Eye solutions & suspensions
      • 5.6.1.2.1. Eye solutions & suspensions market revenue estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.6.1.3. Capsules & tablets
      • 5.6.1.3.1. Capsules & tablets market revenue estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.6.1.4. Eye drops
      • 5.6.1.4.1. Eye drops market revenue estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.6.1.5. Ointments
      • 5.6.1.5.1. Ointments market revenue estimates and forecasts, 2018 - 2030 (USD Million)
• 5.7. Infection
  • 5.7.1. Infection market revenue estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.7.1.1. Gels
      • 5.7.1.1.1. Gels market revenue estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.7.1.2. Eye solutions & suspensions
      • 5.7.1.2.1. Eye solutions & suspensions market revenue estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.7.1.3. Capsules & tablets
      • 5.7.1.3.1. Capsules & tablets market revenue estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.7.1.4. Eye drops
      • 5.7.1.4.1. Eye drops market revenue estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.7.1.5. Ointments
      • 5.7.1.5.1. Ointments market revenue estimates and forecasts, 2018 - 2030 (USD Million)
• 5.8. Retinal Disorders
  • 5.8.1. Retinal disorders market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.8.2. By Dosage Type
    • 5.8.2.1. Gels
      • 5.8.2.1.1. Gels market revenue estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.8.2.2. Eye solutions & suspensions
      • 5.8.2.2.1. Eye solutions & suspensions market revenue estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.8.2.3. Capsules & tablets
      • 5.8.2.3.1. Capsules & tablets market revenue estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.8.2.4. Eye drops
      • 5.8.2.4.1. Eye drops market revenue estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.8.2.5. Ointments
      • 5.8.2.5.1. Ointments market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.8.3. By Type
    • 5.8.3.1. Macular degeneration
      • 5.8.3.1.1. Macular degeneration market revenue estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.8.3.2. Diabetic retinopathy
      • 5.8.3.2.1. Diabetic retinopathy market revenue estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.8.3.3. Others
      • 5.8.3.3.1. Others market revenue estimates and forecasts, 2018 - 2030 (USD Million)
• 5.9. Uveitis
  • 5.9.1. Uveitis market revenue estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.9.1.1. Gels
      • 5.9.1.1.1. Gels market revenue estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.9.1.2. Eye solutions & suspensions
      • 5.9.1.2.1. Eye solutions & suspensions market revenue estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.9.1.3. Capsules & tablets
      • 5.9.1.3.1. Capsules & tablets market revenue estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.9.1.4. Eye drops
      • 5.9.1.4.1. Eye drops market revenue estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.9.1.5. Ointments
      • 5.9.1.5.1. Ointments market revenue estimates and forecasts, 2018 - 2030 (USD Million)
• 5.10. Others
  • 5.10.1. Others market revenue estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.10.1.1. Gels
      • 5.10.1.1.1. Gels market revenue estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.10.1.2. Eye solutions & suspensions
      • 5.10.1.2.1. Eye solutions & suspensions market revenue estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.10.1.3. Capsules & tablets
      • 5.10.1.3.1. Capsules & tablets market revenue estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.10.1.4. Eye drops
      • 5.10.1.4.1. Eye drops market revenue estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.10.1.5. Ointments
      • 5.10.1.5.1. Ointments market revenue estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 6. Ophthalmic Drugs Market: Route of Administration Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Ophthalmic Drugs Market: Route of Administration Movement Analysis
• 6.3. Ophthalmic Drugs Market Size & Trend Analysis, by Route of Administration, 2018 to 2030 (USD Million)
• 6.4. Topical
  • 6.4.1. Topical market revenue estimates and forecasts, 2018 - 2030 (USD Million)
• 6.5. Local Ocular
  • 6.5.1. Local ocular market revenue estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.5.1.1. Subconjunctival
      • 6.5.1.1.1. Subconjunctival market revenue estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.5.1.2. Intravitreal
      • 6.5.1.2.1. Intravitreal market revenue estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.5.1.3. Retrobulbar
      • 6.5.1.3.1. Retrobulbar market revenue estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.5.1.4. Intracameral
      • 6.5.1.4.1. Intracameral market revenue estimates and forecasts, 2018 - 2030 (USD Million)
• 6.6. Sytemic
  • 6.6.1. Sytemic market revenue estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 7. Ophthalmic Drugs Market: Dosage Type Estimates & Trend Analysis

• 7.1. Segment Dashboard
• 7.2. Ophthalmic Drugs Market: Dosage Type Movement Analysis
• 7.3. Ophthalmic Drugs Market Size & Trend Analysis, by Dosage Type, 2018 to 2030 (USD Million)
• 7.4. Gels
  • 7.4.1. Gels market revenue estimates and forecasts, 2018 - 2030 (USD Million)
• 7.5. Eye solutions & suspensions
  • 7.5.1. Eye solutions & suspensions market revenue estimates and forecasts, 2018 - 2030 (USD Million)
• 7.6. Capsules & Tablets
  • 7.6.1. Capsules & tablets market revenue estimates and forecasts, 2018 - 2030 (USD Million)
• 7.7. Eye drops
  • 7.7.1. Eye drops market revenue estimates and forecasts, 2018 - 2030 (USD Million)
• 7.8. Ointments
  • 7.8.1. Ointments market revenue estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 8. Ophthalmic Drugs Market: Product Type Estimates & Trend Analysis

• 8.1. Segment Dashboard
• 8.2. Ophthalmic Drugs Market: Product Type Movement Analysis
• 8.3. Ophthalmic Drugs Market Size & Trend Analysis, by Product Type, 2018 to 2030 (USD Million)
• 8.4. OTC
  • 8.4.1. OTC market revenue estimates and forecasts, 2018 - 2030 (USD Million)
• 8.5. Prescription Drugs
  • 8.5.1. Prescription drugs market revenue estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 9. Ophthalmic Drugs Market: Drug Type Estimates & Trend Analysis

• 9.1. Segment Dashboard
• 9.2. Ophthalmic Drugs Market: Drug Type Movement Analysis
• 9.3. Ophthalmic Drugs Market Size & Trend Analysis, by Drug Type, 2018 to 2030 (USD Million)
• 9.4. Branded Drugs
  • 9.4.1. Branded drugs market revenue estimates and forecasts, 2018 - 2030 (USD Million)
• 9.5. Generic Drugs
  • 9.5.1. Generic drugs market revenue estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 10. Ophthalmic Drugs Market: Regional Estimates & Trend Analysis

• 10.1. Regional Market Share Analysis, 2023 & 2030
• 10.2. Regional Market Dashboard
• 10.3. Global Regional Market Snapshot
• 10.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 10.5. North America
  • 10.5.1. U.S.
    • 10.5.1.1. Key country dynamics
    • 10.5.1.2. Regulatory framework/Reimbursement
    • 10.5.1.3. Competitive scenario
    • 10.5.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 10.5.2. Canada
    • 10.5.2.1. Key country dynamics
    • 10.5.2.2. Regulatory framework/Reimbursement
    • 10.5.2.3. Competitive scenario
    • 10.5.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 10.5.3. Mexico
    • 10.5.3.1. Key country dynamics
    • 10.5.3.2. Regulatory framework/Reimbursement
    • 10.5.3.3. Competitive scenario
    • 10.5.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
• 10.6. Europe
  • 10.6.1. UK
    • 10.6.1.1. Key country dynamics
    • 10.6.1.2. Regulatory framework/Reimbursement
    • 10.6.1.3. Competitive scenario
    • 10.6.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 10.6.2. Germany
    • 10.6.2.1. Key country dynamics
    • 10.6.2.2. Regulatory framework/Reimbursement
    • 10.6.2.3. Competitive scenario
    • 10.6.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 10.6.3. France
    • 10.6.3.1. Key country dynamics
    • 10.6.3.2. Regulatory framework/Reimbursement
    • 10.6.3.3. Competitive scenario
    • 10.6.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 10.6.4. Italy
    • 10.6.4.1. Key country dynamics
    • 10.6.4.2. Regulatory framework/Reimbursement
    • 10.6.4.3. Competitive scenario
    • 10.6.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 10.6.5. Spain
    • 10.6.5.1. Key country dynamics
    • 10.6.5.2. Regulatory framework/Reimbursement
    • 10.6.5.3. Competitive scenario
    • 10.6.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 10.6.6. Norway
    • 10.6.6.1. Key country dynamics
    • 10.6.6.2. Regulatory framework/Reimbursement
    • 10.6.6.3. Competitive scenario
    • 10.6.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 10.6.7. Sweden
    • 10.6.7.1. Key country dynamics
    • 10.6.7.2. Regulatory framework/Reimbursement
    • 10.6.7.3. Competitive scenario
    • 10.6.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 10.6.8. Denmark
    • 10.6.8.1. Key country dynamics
    • 10.6.8.2. Regulatory framework/Reimbursement
    • 10.6.8.3. Competitive scenario
    • 10.6.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 10.7. Asia Pacific
  • 10.7.1. Japan
    • 10.7.1.1. Key country dynamics
    • 10.7.1.2. Regulatory framework/Reimbursement
    • 10.7.1.3. Competitive scenario
    • 10.7.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 10.7.2. China
    • 10.7.2.1. Key country dynamics
    • 10.7.2.2. Regulatory framework/Reimbursement
    • 10.7.2.3. Competitive scenario
    • 10.7.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 10.7.3. India
    • 10.7.3.1. Key country dynamics
    • 10.7.3.2. Regulatory framework/Reimbursement
    • 10.7.3.3. Competitive scenario
    • 10.7.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 10.7.4. Australia
    • 10.7.4.1. Key country dynamics
    • 10.7.4.2. Regulatory framework/Reimbursement
    • 10.7.4.3. Competitive scenario
    • 10.7.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 10.7.5. South Korea
    • 10.7.5.1. Key country dynamics
    • 10.7.5.2. Regulatory framework/Reimbursement
    • 10.7.5.3. Competitive scenario
    • 10.7.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 10.7.6. Thailand
    • 10.7.6.1. Key country dynamics
    • 10.7.6.2. Regulatory framework/Reimbursement
    • 10.7.6.3. Competitive scenario
    • 10.7.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 10.8. Latin America
  • 10.8.1. Brazil
    • 10.8.1.1. Key country dynamics
    • 10.8.1.2. Regulatory framework/Reimbursement
    • 10.8.1.3. Competitive scenario
    • 10.8.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 10.8.2. Argentina
    • 10.8.2.1. Key country dynamics
    • 10.8.2.2. Regulatory framework/Reimbursement
    • 10.8.2.3. Competitive scenario
    • 10.8.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 10.9. MEA
  • 10.9.1. South Africa
    • 10.9.1.1. Key country dynamics
    • 10.9.1.2. Regulatory framework/Reimbursement
    • 10.9.1.3. Competitive scenario
    • 10.9.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 10.9.2. Saudi Arabia
    • 10.9.2.1. Key country dynamics
    • 10.9.2.2. Regulatory framework/Reimbursement
    • 10.9.2.3. Competitive scenario
    • 10.9.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 10.9.3. UAE
    • 10.9.3.1. Key country dynamics
    • 10.9.3.2. Regulatory framework/Reimbursement
    • 10.9.3.3. Competitive scenario
    • 10.9.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 10.9.4. Kuwait
    • 10.9.4.1. Key country dynamics
    • 10.9.4.2. Regulatory framework
    • 10.9.4.3. Competitive scenario
    • 10.9.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 11. Competitive Landscape

• 11.1. Recent Developments & Impact Analysis, By Key Market Participants
• 11.2. Company/Competition Categorization
• 11.3. Vendor Landscape
  • 11.3.1. List of key distributors and channel partners
  • 11.3.2. Key customers
  • 11.3.3. Key company market share analysis, 2023
  • 11.3.4. Alcon
    • 11.3.4.1. Company overview
    • 11.3.4.2. Financial performance
    • 11.3.4.3. Services benchmarking
    • 11.3.4.4. Strategic initiatives
  • 11.3.5. Novartis AG
    • 11.3.5.1. Company overview
    • 11.3.5.2. Financial performance
    • 11.3.5.3. Services benchmarking
    • 11.3.5.4. Strategic initiatives
  • 11.3.6. Bausch Health Companies, Inc.
    • 11.3.6.1. Company overview
    • 11.3.6.2. Financial performance
    • 11.3.6.3. Services benchmarking
    • 11.3.6.4. Strategic initiatives
  • 11.3.7. Merck & Co., Inc.
    • 11.3.7.1. Company overview
    • 11.3.7.2. Financial performance
    • 11.3.7.3. Services benchmarking
    • 11.3.7.4. Strategic initiatives
  • 11.3.8. Regeneron Pharmaceuticals, Inc.
    • 11.3.8.1. Company overview
    • 11.3.8.2. Financial performance
    • 11.3.8.3. Services benchmarking
    • 11.3.8.4. Strategic initiatives
  • 11.3.9. Coherus BioSciences, Inc.
    • 11.3.9.1. Company overview
    • 11.3.9.2. Financial performance
    • 11.3.9.3. Services benchmarking
    • 11.3.9.4. Strategic initiatives
  • 11.3.10. AbbVie, Inc. (Allergan)
    • 11.3.10.1. Company overview
    • 11.3.10.2. Financial performance
    • 11.3.10.3. Services benchmarking
    • 11.3.10.4. Strategic initiatives
  • 11.3.11. Pfizer, Inc.
    • 11.3.11.1. Company overview
    • 11.3.11.2. Financial performance
    • 11.3.11.3. Services benchmarking
    • 11.3.11.4. Strategic initiatives
  • 11.3.12. Bayer AG
    • 11.3.12.1. Company overview
    • 11.3.12.2. Financial performance
    • 11.3.12.3. Services benchmarking
    • 11.3.12.4. Strategic initiatives
  • 11.3.13. Santen Pharmaceutical Co., Ltd.
    • 11.3.13.1. Company overview
    • 11.3.13.2. Financial performance
    • 11.3.13.3. Services benchmarking
    • 11.3.13.4. Strategic initiatives
  • 11.3.14. Roche (Genentech, Inc.)
    • 11.3.14.1. Company overview
    • 11.3.14.2. Financial performance
    • 11.3.14.3. Services benchmarking
    • 11.3.14.4. Strategic initiatives
  • 11.3.15. Nicox
    • 11.3.15.1. Company overview
    • 11.3.15.2. Financial performance
    • 11.3.15.3. Services benchmarking
    • 11.3.15.4. Strategic initiatives

관련자료